Reproducible and Quantifiable Directed In Vivo Angiogenesis Assessment Assay

AMSBIO has announced a new range of Directed in vivo Angiogenesis Assay (DIVAA™) kits that address the short-comings of the traditional plug assay by controlling the site for angiogenesis, increasing reproducibility, conserving test compounds, and supplying more statistical data for quantitative analysis. This range of kits is designed to test for activation, inhibition and tube formation.

The Directed In Vivo Angiogenesis Assay (DIVAA™) is the first in vivo system for the study of angiogenesis that provides quantitative and reproducible results. The DIVAA kits provide implant grade silicone cylinders closed at one end, called angioreactors. The angioreactors are filled with 20 microlitres of AMSBIO's Basement Membrane Extract (BME) premixed with or without angiogenesis modulating factors. These angioreactors are then implanted subcutaneously in the dorsal flanks of nude mice.

With the onset of angiogenesis, cellular vascularization proceeds to invade the angioreactor, and as early as nine days post-implantation, there are enough cells to determine an effective dose response to angiogenic modulating factors. The sleek design of the patented angioreactor optimizes sensitivity and allows for up to four units per mouse, giving a more controlled experiment and decreasing the number of mice required for a study.

Tumour cells can be implanted into the angioreactor, to study their angiogenic effects in an in vivo system. AMSBIO's DIVAA Kit is provided with FITC-Lectin for fluorescent quantitative analysis. Optional protocols are available for analysis with Calcein-AM and Dextran-FITC.

For further information please visit the company article page.